在人源化 BLT 小鼠中生成 HIV 潜伏期。
Generation of HIV latency in humanized BLT mice.
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Center for AIDS Research, University of North Carolina, Chapel Hill, North Carolina, USA.
出版信息
J Virol. 2012 Jan;86(1):630-4. doi: 10.1128/JVI.06120-11. Epub 2011 Oct 19.
Abstract
Here we demonstrate that a combination of tenofovir, emtricitabine, and raltegravir effectively suppresses peripheral and systemic HIV replication in humanized BLT mice. We also demonstrate that antiretroviral therapy (ART)-treated humanized BLT mice harbor latently infected resting human CD4+ T cells that can be induced ex vivo to produce HIV. We observed that the levels of infected resting human CD4+ T cells present in BLT mice are within the range of those observed circulating in patients undergoing suppressive ART. These results demonstrate the potential of humanized BLT mice as an attractive model for testing the in vivo efficacy of novel HIV eradication strategies.
摘要
在这里，我们证明了替诺福韦、恩曲他滨和拉替拉韦的联合治疗可以有效地抑制人源化 BLT 小鼠的外周和全身 HIV 复制。我们还证明，接受抗逆转录病毒治疗（ART）的人源化 BLT 小鼠携带潜伏感染的静止人类 CD4+T 细胞，这些细胞可以在体外被诱导产生 HIV。我们观察到，BLT 小鼠中存在的感染静止人类 CD4+T 细胞的水平在接受抑制性 ART 的患者中观察到的循环水平范围内。这些结果表明，人源化 BLT 小鼠作为一种有吸引力的模型，可用于测试新型 HIV 清除策略的体内疗效。
相似文献
1
Generation of HIV latency in humanized BLT mice.在人源化 BLT 小鼠中生成 HIV 潜伏期。
J Virol. 2012 Jan;86(1):630-4. doi: 10.1128/JVI.06120-11. Epub 2011 Oct 19.
2
HIV latency in the humanized BLT mouse.人源化 BLT 小鼠中的 HIV 潜伏期。
J Virol. 2012 Jan;86(1):339-47. doi: 10.1128/JVI.06366-11. Epub 2011 Nov 9.
3
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.帕比司他对细胞相关HIV RNA和DNA水平及潜伏性HIV感染影响的体内分析。
Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.
4
HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.在抑制性口服联合抗逆转录病毒疗法期间，人源化NSG小鼠模型中的HIV复制与潜伏
J Virol. 2018 Mar 14;92(7). doi: 10.1128/JVI.02118-17. Print 2018 Apr 1.
5
HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.新型人源化 T 细胞唯一小鼠（TOM）模型中的 HIV-1 感染、治疗反应和病毒潜伏期建立。
Retrovirology. 2013 Oct 24;10:121. doi: 10.1186/1742-4690-10-121.
6
Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse.人源化 Rag2⁻/⁻ γc⁻/⁻ 小鼠中静止 CD4⁺ T 细胞潜伏 HIV-1 感染。
J Virol. 2012 Jan;86(1):114-20. doi: 10.1128/JVI.05590-11. Epub 2011 Oct 19.
7
Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1 and TIGIT CD4 T Cells.人源化 HIV-1 潜伏感染小鼠模型，在 PD-1 和 TIGIT CD4 T 细胞中富集潜伏病毒。
J Virol. 2019 May 1;93(10). doi: 10.1128/JVI.02086-18. Print 2019 May 15.
8
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.长期接受抗逆转录病毒治疗患者体内HIV储存库的衰减：对病毒根除的意义
J Infect Dis. 2007 Jun 15;195(12):1762-4. doi: 10.1086/518250. Epub 2007 May 2.
9
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.马拉维若与潜伏 HIV-1 再激活有关，通过抑制性抗逆转录病毒治疗的 HIV 感染者静息 CD4 T 细胞中 NF-κB 的激活。
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01931-17. Print 2018 May 1.
10
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice.在人类免疫缺陷病毒感染的人源化BLT小鼠中诱导强大的细胞和体液病毒特异性适应性免疫反应。
J Virol. 2009 Jul;83(14):7305-21. doi: 10.1128/JVI.02207-08. Epub 2009 May 6.
引用本文的文献
1
Natural Killer Cell Therapy Combined with Probiotic Bacteria Supplementation Restores Bone Integrity in Cancer by Promoting IFN-γ Production.自然杀伤细胞疗法联合补充益生菌通过促进γ-干扰素的产生来恢复癌症患者的骨完整性。
Cells. 2025 Aug 29;14(17):1347. doi: 10.3390/cells14171347.
2
Can Humanized Immune System Mouse and Rat Models Accelerate the Development of Cytomegalovirus-Based Vaccines Against Infectious Diseases and Cancers?人源化免疫系统小鼠和大鼠模型能否加速基于巨细胞病毒的抗传染病和癌症疫苗的研发？
Int J Mol Sci. 2025 Mar 27;26(7):3082. doi: 10.3390/ijms26073082.
3
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption.双特异性抗体治疗中自然杀伤细胞的耗竭与抗逆转录病毒治疗中断后缺乏对HIV的控制有关。
Commun Biol. 2025 Feb 14;8(1):236. doi: 10.1038/s42003-025-07651-6.
4
The Intersection of HIV and Pulmonary Vascular Health: From HIV Evolution to Vascular Cell Types to Disease Mechanisms.HIV与肺血管健康的交叉领域：从HIV演变到血管细胞类型再到疾病机制
J Vasc Dis. 2024 Jun;3(2):174-200. doi: 10.3390/jvd3020015. Epub 2024 May 6.
5
Long-Term Human Immune Reconstitution, T-Cell Development, and Immune Reactivity in Mice Lacking the Murine Major Histocompatibility Complex: Validation with Cellular and Gene Expression Profiles.长期的人类免疫重建、T 细胞发育和缺乏小鼠主要组织相容性复合体的小鼠免疫反应性：基于细胞和基因表达谱的验证。
Cells. 2024 Oct 12;13(20):1686. doi: 10.3390/cells13201686.
6
In situ analysis of neuronal injury and neuroinflammation during HIV-1 infection.在 HIV-1 感染期间对神经元损伤和神经炎症的原位分析。
Retrovirology. 2024 Jul 1;21(1):11. doi: 10.1186/s12977-024-00644-z.
7
Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.探讨 HIV 感染中的慢性炎症、免疫代谢和 T 细胞功能障碍。
Viruses. 2024 Jan 31;16(2):219. doi: 10.3390/v16020219.
8
Current Advances in Humanized Mouse Models for Studying NK Cells and HIV Infection.用于研究自然杀伤细胞和HIV感染的人源化小鼠模型的当前进展
Microorganisms. 2023 Aug 2;11(8):1984. doi: 10.3390/microorganisms11081984.
9
A germ-free humanized mouse model shows the contribution of resident microbiota to human-specific pathogen infection.无菌人源化小鼠模型显示了定植菌群对人类特有的病原体感染的贡献。
Nat Biotechnol. 2024 Jun;42(6):905-915. doi: 10.1038/s41587-023-01906-5. Epub 2023 Aug 10.
10
Humanized Mice for Studies of HIV-1 Persistence and Elimination.用于研究HIV-1持续性和清除的人源化小鼠
Pathogens. 2023 Jun 27;12(7):879. doi: 10.3390/pathogens12070879.
本文引用的文献
1
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.将 1%的替诺福韦局部应用于人源化 BLT 小鼠，并按照 CAPRISA 004 实验设计使用，证明对阴道 HIV 感染具有部分保护作用，验证了 BLT 模型在评估新的杀微生物候选药物中的有效性。
J Virol. 2011 Aug;85(15):7582-93. doi: 10.1128/JVI.00537-11. Epub 2011 May 18.
2
Eradication therapies for HIV Infection: time to begin again.HIV感染的根除疗法：是时候重新开始了。
AIDS Res Hum Retroviruses. 2011 Apr;27(4):347-53. doi: 10.1089/AID.2011.0017. Epub 2011 Mar 11.
3
Simian immunodeficiency virus macaque models of HIV latency.猿猴免疫缺陷病毒猴 HIV 潜伏期模型。
Curr Opin HIV AIDS. 2011 Jan;6(1):57-61. doi: 10.1097/COH.0b013e32834086ce.
4
Introduction: challenges to finding a cure for HIV infection.引言：寻找治愈 HIV 感染的挑战。
Curr Opin HIV AIDS. 2011 Jan;6(1):1-3. doi: 10.1097/COH.0b013e328340ffa6.
5
Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.靶向病毒储存库：抗逆转录病毒疗法停止病毒复制的能力。
Curr Opin HIV AIDS. 2011 Jan;6(1):49-56. doi: 10.1097/COH.0b013e32834134ea.
6
Curing HIV: Pharmacologic approaches to target HIV-1 latency.治愈 HIV：靶向 HIV-1 潜伏期的药物治疗方法。
Annu Rev Pharmacol Toxicol. 2011;51:397-418. doi: 10.1146/annurev-pharmtox-010510-100237.
7
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.尽管 HIV 储存库水平极低，但停止抗逆转录病毒治疗后血浆病毒血症反弹：对根除的影响。
AIDS. 2010 Nov 27;24(18):2803-8. doi: 10.1097/QAD.0b013e328340a239.
8
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.在接受抑制性抗逆转录病毒治疗的 HIV 阳性患者的肠道内，HIV 负担和免疫激活存在差异。
J Infect Dis. 2010 Nov 15;202(10):1553-61. doi: 10.1086/656722. Epub 2010 Oct 12.
9
Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice.人源化 NOD/SCID/IL2rgammanull 小鼠中的 Th1 和 Th17 免疫能力。
Hum Immunol. 2010 Jun;71(6):551-9. doi: 10.1016/j.humimm.2010.02.019. Epub 2010 Mar 26.
10
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.暴露前全身给予抗逆转录病毒药物可预防人源化 BLT 小鼠直肠和静脉内 HIV-1 的传播。
PLoS One. 2010 Jan 21;5(1):e8829. doi: 10.1371/journal.pone.0008829.
Zotero 插件